[Skip to Content]
[Skip to Content Landing]
Evidence to Practice
January 2016

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors for Treatment of High Cholesterol Levels: Effectiveness and Value

Author Affiliations
  • 1Division of General Internal Medicine, Department of Medicine, University of California, San Francisco
  • 2Division of Cardiology, Department of Medicine, University of California San Francisco
  • 3Department of Epidemiology and Biostatistics, University of California, San Francisco
  • 4Center for Healthcare Value, University of California, San Francisco
  • 5Institute for Clinical and Economic Review, Boston, Massachusetts
JAMA Intern Med. 2016;176(1):107-108. doi:10.1001/jamainternmed.2015.7248

The Institute for Clinical and Economic Review developed an evidence report, including a systematic review of the literature, a cost-effectiveness model, and a budget impact assessment, to support a public meeting of the New England Comparative Effectiveness Public Advisory Council (CEPAC) on October 27, 2015.1 The report evaluates the comparative clinical effectiveness and comparative value of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors as a class for the treatment of adults with familial hypercholesterolemia or cardiovascular disease (CVD) who require additional lowering of low-density lipoprotein cholesterol (LDL-C) levels.